Lp(a) Is an Independent Cardiovascular Risk Factor, And the VESALIUS-CV Data Just Reinforced It

*Originally surfaced May 12, 2026.*

VESALIUS-CV results published in Circulation in May 2026 reinforced something cardiology has been moving toward for several years: lipoprotein(a), abbreviated Lp(a), is an independent risk factor for major coronary events, and it stays a risk factor even when standard LDL cholesterol is well controlled. In a primary-prevention population with atherosclerosis or high-risk diabetes but no prior myocardial infarction or stroke, baseline Lp(a) was independently linked to subsequent major coronary events, with the strongest signal for heart attack specifically.

This is consistent with the 2026 American College of Cardiology and American Heart Association lipid guidance, which recommends measuring Lp(a) at least once in adulthood. High Lp(a), often defined as 125 nmol/L or greater (or 50 mg/dL or greater), is associated with about a 1.4-fold long-term increase in heart attack and stroke risk. Levels of 250 nmol/L or greater carry at least a twofold increased risk.

## Why Lp(a) is different

Lp(a) is largely genetic. Levels are set early in life, stay relatively stable, and respond very little to diet, exercise, or statins. People with high Lp(a) have been carrying that risk their whole adult life whether or not anyone measured it.

That is the core argument for measuring Lp(a) at least once: it adds information that a standard lipid panel will not give you, and the answer is durable. A single Lp(a) reading in adulthood is usually enough.

## How this changes what to do

A high Lp(a) reading does not yet have an FDA-approved targeted therapy. Several investigational Lp(a)-lowering drugs (pelacarsen, olpasiran, lepodisiran, zerlasiran, muvalaplin) have shown substantial Lp(a) reduction in trials, and a phase 3 cardiovascular outcomes trial, ACCLAIM-Lp(a), is enrolling. None of those are available in clinical practice in mid-2026.

What a high Lp(a) reading does change is how aggressive the rest of the cardiovascular plan should be. Cleveland Clinic and others have noted that Lp(a)-associated cardiovascular risk is amplified when apolipoprotein B (ApoB) is also elevated. That argues for measuring ApoB alongside Lp(a) and for treating elevated ApoB aggressively even when LDL cholesterol on a standard panel looks acceptable.

## The lab options

For a one-time Lp(a) check in adulthood, LevelPanel offers the Lp(a) test. For a more complete cardiovascular-risk picture, the ApoB test is the higher-resolution alternative to the standard lipid panel for measuring atherogenic particle burden. The NMR LipoProfile provides particle-number detail on LDL subtypes. The heart health panel packages several of these together.

For general background, see our high cholesterol page and our heart disease risk page.

This article is editorial commentary and is not medical advice. Cardiovascular risk decisions should be made with a clinician who can integrate Lp(a), ApoB, blood pressure, family history, and other inputs.